Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

P0094

Sigma-Aldrich

Perindopril erbumine

Sinónimos:

(2S,3aS,7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid tert-butylamine salt, S-9490

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

50 MG
$155.000
250 MG
$585.000

$155.000

Fecha estimada de envío20 de abril de 2025

Solicitar un pedido a granel
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
50 MG
$155.000
250 MG
$585.000

About This Item

Fórmula empírica (notación de Hill):
C19H32N2O5 · C4H11N
Número de CAS:
107133-36-8
Peso molecular:
441.60
MDL number:
MFCD02313824
UNSPSC Code:
12352200
PubChem Substance ID:
329820011
NACRES:
NA.77

$155.000

Fecha estimada de envío20 de abril de 2025

Solicitar un pedido a granel

assay

≥98% (HPLC)

Quality Level

100

form

powder

solubility

H2O: 10 mg/mL, clear

originator

Xoma

storage temp.

2-8°C

SMILES string

CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC

InChI

1S/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14-,15-,16-;/m0./s1

InChI key

IYNMDWMQHSMDDE-MHXJNQAMSA-N

Gene Information

human ... ACE(1636)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive.
Perindopril erbumine is an angiotensin converting enzyme (ACE) inhibitor; antihypertensive; becomes hydrolyzed in vivo to the active diacid metabolite; unlike the other ACE inhibitors, inhibits tumor growth in hepatocellular carcinoma cells due to suppression of VEGF levels; also suppresses angiotensin II production in vitro. Long-term therapy with this agent has a beneficial effect on the cerebral circulation by improving cerebral perfusion reserve in patients with previous minor stroke.

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Xoma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000180727
0000180726
0000193600
014M4701V
062M4747V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Losartan Potassium

Supelco

61188

Losartan Potassium

Chris Tikellis et al.
Clinical science (London, England : 1979), 124(10), 617-626 (2012-12-12)
It is recommended that individuals with diabetes restrict their dietary sodium intake. However, although salt intake is correlated with BP (blood pressure), it also partly determines the activation state of the RAAS (renin-angiotensin-aldosterone system), a key mediator of diabetes-associated atherosclerosis.
Linda Battes et al.
The American journal of cardiology, 112(1), 27-33 (2013-04-06)
Appropriate risk stratification of patients with established, stable coronary artery disease could contribute to the prevention of recurrent cardiovascular events. The purpose of the present study was to develop and validate risk prediction models for various cardiovascular end points in
Kate T Murphy et al.
International journal of cancer, 133(5), 1234-1246 (2013-02-26)
Cancer cachexia describes the progressive skeletal muscle wasting and weakness associated with many cancers. Cachexia reduces mobility and quality of life and accounts for 20-30% of all cancer-related deaths. Activation of the renin-angiotensin system causes skeletal muscle wasting and weakness.
Ruth Peters et al.
Age and ageing, 42(2), 253-258 (2012-08-23)
numerous reports have linked impaired kidney function to a higher risk of cardiovascular events and mortality. There are relatively few data relating to kidney function in the very elderly. the Hypertension in the Very Elderly Trial (HYVET) was a randomised
Omar Mukhtar et al.
British journal of clinical pharmacology, 75(4), 951-954 (2012-08-18)
Early trials in the field of hypertension focused on adults in their fifties and sixties. However, with the passage of time, a progressive effort has been made to expand the evidence base for treatment in older adults. 2008 saw publication
Ver todos los artículos relacionados

Artículos

Angiotensin Receptors

We offer many products related to angiotensin receptors for your research needs.

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico